Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist [Seeking Alpha]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Dravet syndrome is a severe form of epilepsy that causes multiple seizure types and developmental disabilities. Stoke's STK-001 demonstrated substantial reductions in convulsive seizure frequency and improvements in cognition and behavior in patients. An approval seems likely, however, investors will need to be patient. An opportunity in ophthalmology and a partnership with Acadia Pharmaceuticals add further value to the company. Investment Overview Stoke Therapeutics' ( NASDAQ: STOK ) stock has been soaring in response to the positive data the company shared from two open-label Phase 1/2a studies and two open-label extension ("OLE") studies of its lead drug candidate STK-001 in children and adolescents ages 2 to 18 with Dravet syndrome, on March 25th this year. Stoke, which raised ~$142m in its 2019 IPO, at $18 per share, leverages its RNA therapeutics platform TANGO ("Targeted Augmentation of Nuclear Gene Output") to create antisense oligonucleotides ("ASO"), and STK-001
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerBusiness Wire
- Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerBusiness Wire
STOK
Earnings
- 3/25/24 - Beat
STOK
Sec Filings
- 4/29/24 - Form 8-K
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- STOK's page on the SEC website